RxDoctor Payments DataLook up a doctor →

Elizabeth Race, MD

Infectious Disease · Dallas, TXNPI 1568424596

Payments from drug & device makers

$1,478,451in general payments, 2019–2025

Across 1,451 payments — averaging $1018.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$817K
  • Janssen Products, LP$365K
  • Pfizer$200K
  • Theratechnologies Inc.$90K
  • Janssen Scientific Affairs, LLC$2K
  • Johnson & Johnson$1K
  • plus $4K from 11 others

What the payments were for

  • Consulting fees$63,0514%
  • Speaking & faculty fees$1,217,28882%
  • Travel & lodging$165,48111%
  • Food & beverage$32,3572%
  • Education$2730%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,478,451 in reported general payments places this provider in the 95th percentile of 576 infectious disease providers in Texas.

See all infectious disease providers in Texas

Medicare billing

Part B allowed, 2024
$5,903
Medicare patients
17
Services billed
63

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TriumeqAbacavir/Dolutegravir/Lamivudi128$452,251
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf95$438,292
DovatoDolutegravir Sodium/Lamivudine101$287,572
PrezcobixDarunavir/Cobicistat114$276,484
JulucaDolutegravir/Rilpivirine43$145,185
RukobiaFostemsavir Tromethamine14$123,412
BiktarvyBictegrav/Emtricit/Tenofov Ala30$118,220
TivicayDolutegravir Sodium50$114,692
DescovyEmtricitabine/Tenofov Alafenam30$65,477
GenvoyaElviteg/Cob/Emtri/Tenof Alafen13$52,390
OdefseyEmtricitab/Rilpiviri/Tenof Ala12$38,687
OzempicSemaglutide33$31,835
EvotazAtazanavir Sulfate/Cobicistat13$20,533
Abacavir-LamivudineAbacavir Sulfate/Lamivudine30$6,607
Emtricitabine20$5,754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyTriumeq, Dovato, Juluca, Rukobia, Tivicay$816,785$1,123,112336 claims
Janssen Products, LPSymtuza$364,822$438,29295 claims
Johnson & JohnsonPrezcobix$1,330$276,484114 claims
GileadBiktarvy, Descovy, Genvoya$1,001$236,08873 claims
Novo NordiskOzempic$87$31,83533 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 576 infectious disease providers in Texas.

Other infectious disease in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →